Table 3. Relationship of BRAF V600E alone or TERT promoter mutation alone or their coexistence with clinicopathological characteristics of papillary thyroid cancer.

	No mutation (n = 232)	TERT mutation only (n = 5)	P value	BRAF mutation only (n = 394)	P value	TERT+ BRAF mutations (n = 22)	P value
Age at diagnosis, y
Mean ± SD	44.9 ± 12.3	53.4 ± 23.0	0.361	46.6 ± 11.8	0.104	60.5 ± 11.2	< 0.001
Range	11–78	25–81		18–79		41–80
≥ 45 y	119 (51.3)	3 (60.0)	1.000	235 (59.6)	0.042	19 (86.4)	0.002
Gender (Female)	178 (76.7)	4 (80.0)	1.000	306 (77.7)	0.786	15 (68.2)	0.370
Tumor size in cm
Mean ± SD	1.36 ± 0.78	1.80 ± 0.95	0.247	1.52 ± 0.86	0.032	3.03 ± 1.55	< 0.001
Range	0.1–4.3	0.5–2.8		0.3–5.0		0.6–7.0
> 1 cm	121 (52.2)	4 (80.0)	0.435	235 (59.6)	0.068	21 (95.5)	< 0.001
HT	114 (49.1)	2 (40.0)	1.000	106 (26.9)	< 0.001	6 (27.3)	0.050
Multifocality	74 (31.9)	0 (0.0)	0.328	118 (29.9)	0.610	11 (50.0)	0.085
Capsular invasion	37 (15.9)	3 (60.0)	0.035	88 (22.3)	0.054	13 (59.1)	< 0.001
Extrathyroidal invasion	23 (9.9)	2 (40.0)	0.088	68 (17.3)	0.012	12 (54.5)	< 0.001
LNM	144 (65.5)*	3 (60.0)*	1.000	267 (73.0)*	0.055	17 (81.0)*	0.150
Late stage (III + IV)	68 (29.3)	1 (20.0)	1.000	151 (38.3)	0.022	16 (72.7)	< 0.001
MAICS score	4.3 ± 0.8	5.5 ± 1.7	0.040	4.5 ± 0.9	0.002	6.4 ± 1.3	< 0.001

Footnotes: Data are expressed as number (percentage). Comparisons were performed between the no mutation group and each of the other three groups (TERT promoter mutation only; BRAF mutation only; TERT + BRAF mutation); P value refers to the comparison of the no mutation group with the group in the column immediately left to the P value column. *The percentage is calculated only in patients with neck dissection. HT, Hashimoto's thyroiditis; LNM: lymph node metastasis.